Matt Mindrum is a month into his new role and recently spoke with IBJ about his vision for the region’s growth, downtown vitality and his new insights into youth apprenticeships.
Obesity drugs like Wegovy and Eli Lilly’s Zepbound are showing promising results in helping people shed pounds. But a law bans Medicare from paying for weight loss drugs. Now, drugmakers and a bipartisan coalition of lawmakers are gearing up to push for that to change next year.
It was a busy year for the Indiana life sciences community, with a flurry of billion-dollar deals, major announcements, and a few setbacks. Here we present the top 10 stories of 2023—the good, the bad and the ugly—about an industry that is often hailed as a key driver of Indiana’s economy.
We’re beginning a conversation that doesn’t assume that economics and creativity live in separate worlds. On the contrary, any successful businessperson will tell you that creativity is essential to success.
Fauna Bio, based in the San Francisco area, said Thursday it will give Lilly access to its AI platform, called Convergence, to support preclinical drug discovery efforts in obesity.
Results of a clinical trial for Point Biopharma’s lead compound fell short of analysts’ expectations, and that development is likely to pressure its investors to decide whether to agree to sell the company to Eli Lilly and Co. for $1.4 billion.
It’s a cliché to say someone who just passed away, as basketball legend George McGinnis did early Thursday, was a good person. But he went beyond that. He was nice to a fault. So nice, in fact, that people took advantage of him.
People who stopped taking Eli Lilly and Co.’s blockbuster drug Zepbound after about eight months regained half the weight they’d lost a year later, yet were significantly thinner than when they had started the obesity drug, according to a new study.
The new drug, called Zepbound, carries a hefty price of $1,059.87 per month, and insurers and health care plans are balking, questioning its affordability. Many employers and government health programs exclude obesity treatments from their coverage.
Mundo Sanchez, CFO of refrigerated-trucking company Renewable Transport Services, said his role as chief financial officer extends far beyond financial reporting.
The company, Carmot Therapeutics, has numerous drugs under development. Its lead asset is a once-a-week injection that is in mid-stage development for the treatment of obesity.
The Indiana Economic Development Corp. is one of seven sponsors of a two-day event happening against the backdrop of the United Nations Climate Change Conference in Dubai.
The two companies have been battling for years over patents for migraine headache drugs—Emgality for Lilly and Anjovy for Teva. Both drugs are once-monthly injections and were approved 13 days apart in September 2018.
The live-work-play campus has been picked to join a new national network designed to connect researchers, entrepreneurs and investors to accelerate the development of health care products and services and speed up health care innovations.
Consideration of a pipeline to pump massive amounts of water from Lafayette to the LEAP Innovation and Research District in Lebanon is revealing major gaps in Indiana’s water-rights laws, some stakeholders say.
